The U.S. Department of Justice has initiated an antitrust investigation into several leading commercial fertilizer producers over allegations they colluded to raise prices, sending shockwaves through the agricultural sector and triggering a selloff in related stocks.
According to people familiar with the matter, the probe is examining whether companies including Nutrien Ltd. (TSX:NTR), Mosaic Co., CF Industries Holdings Inc., Koch Inc., and Norway’s Yara International ASA engaged in coordinated pricing practices that could violate civil and criminal antitrust laws. The investigation is being conducted out of the DOJ’s Chicago office and remains in its early stages, the sources said.
The companies under scrutiny control the vast majority of the U.S. fertilizer market. Nutrien and Mosaic together account for approximately 90% of potash and phosphate production capacity in the country, while Nutrien, CF Industries, Koch, and Yara control an estimated 82% of the nitrogen-based fertilizer segment, according to industry watchdog Farm Action.
None of the companies have been formally accused of wrongdoing, and investigations of this nature do not necessarily result in charges or lawsuits. However, the news weighed heavily on market sentiment. Mosaic shares fell as much as 4.3%, CF Industries dropped 5.5%—its steepest decline since November—and Nutrien slid 2.9% on the Toronto Stock Exchange.
Despite the immediate market reaction, analysts suggest the underlying investment thesis for Nutrien remains intact. As one of the world’s largest producers and distributors of crop nutrients, the Saskatchewan-based company benefits from structural demand tied to global food security—a need that persists regardless of economic cycles.
Nutrien’s vertically integrated business model, which combines large-scale production with North America’s largest agricultural retail network, provides earnings stability and growth optionality. The company offers a dividend yield of approximately 3% and has increased its payout by 20% over the past five years, supported by a strong balance sheet and ongoing share repurchases.
Trading at a forward price-to-earnings multiple of just 12 times—below many growth stocks and some industry peers—Nutrien presents what some investors view as a compelling valuation case.
The antitrust probe introduces near-term uncertainty, but does not fundamentally alter the company’s competitive positioning or long-term exposure to rising global food demand. For income-oriented investors with a long horizon, the recent pullback may offer a measured entry point, though traders should remain mindful of headline risk as the investigation unfolds.
